Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

NCT04987229 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT04987229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04987229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Lead sponsor
Alkermes, Inc.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
October 22, 2021
Completion date
September 30, 2027
Enrollment
236 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder, schizophrenia